Mavenclad

Novartis, Merck KGaA and Biogen: Which new MS drug do doctors like best? You might be surprised
Fierce Pharma
Tue, 11/19/19 - 02:41 pm
MS
multiple sclerosis
physicians
Novartis
Mayzent
Merck KGaA
Mavenclad
Biogen
Vumerity
German Merck finally gets yes for MS drug Mavenclad
Biopharma Dive
Tue, 04/2/19 - 04:20 pm
FDA
Merck KGaA
Mavenclad
MS
multiple sclerosis
Analyst sees positive future for Merck KGaA in MS market, as FDA accepts Mavenclad for review
The Pharma Letter
Wed, 08/1/18 - 10:43 am
Merck KGaA
Mavenclad
cladribine
MS
multiple sclerosis